5 Key Takeaways
-
1
Rayner acquired US distribution rights to Anikavisc, enhancing its cataract ecosystem and portfolio of solutions.
-
2
Anikavisc is an ophthalmic viscosurgical device that protects the corneal endothelium and maintains anterior chamber depth.
-
3
The acquisition coincides with the US launch of Rayner's FDA-approved Sophi phaco platform and the RayOne EMV Toric IOL.
-
4
Rayner aims to provide a comprehensive portfolio by 2026, including premium IOLs, OVD, and advanced phaco technology.
-
5
The acquisition will improve customer support and streamline purchasing for Anikavisc users through Rayner's direct sales team.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
